PE20221006A1 - Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae" - Google Patents

Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae"

Info

Publication number
PE20221006A1
PE20221006A1 PE2022000118A PE2022000118A PE20221006A1 PE 20221006 A1 PE20221006 A1 PE 20221006A1 PE 2022000118 A PE2022000118 A PE 2022000118A PE 2022000118 A PE2022000118 A PE 2022000118A PE 20221006 A1 PE20221006 A1 PE 20221006A1
Authority
PE
Peru
Prior art keywords
group
phenyl
alkyl
enterobacteriaceae
treatment
Prior art date
Application number
PE2022000118A
Other languages
English (en)
Inventor
Paul Meo
Mohammed Nawaz Khan
Cedric Charrier
Original Assignee
Discuva Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60664899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20221006(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Discuva Ltd filed Critical Discuva Ltd
Publication of PE20221006A1 publication Critical patent/PE20221006A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Warehouses Or Storage Devices (AREA)

Abstract

La presente invencion se refiere a compuestos de formula general (II) donde X1 es NR1 ; R1 se selecciona de hidrogeno o alquilo C1-2; R2 se selecciona del grupo que consiste en S(sulfinilo), O(oxo), ciano, -CH2NR5R6, metilo (-CH3), halogeno, hidroxilo, -CONR3R4 y COOH; R3 y R4 se seleccionan independientemente del grupo que consiste en hidrogeno, alquilo C1-3, COR5 , CONR5R6 , CO2R5 , alquilo C1-2-NR5R6 ; o R3 y R4 junto con el atomo de nitrogeno al que estan unidos forman un grupo amino ciclico monociclico de 4 a 7 miembros, cuyo grupo esta opcionalmente sustituido con uno o mas sustituyentes seleccionados del grupo que consiste en NR5R6 , alcoxi C1-2 y oxo; R5 y R6 se seleccionan independientemente del grupo que consiste en hidrogeno y alquilo C1-4; R7 se selecciona del grupo que consiste en fenilo, heterociclilo monociclico de 5 a 7 miembros y heteroarilo monociclico de 5 o 6 miembros, en donde el fenilo, entre otros; R10 se selecciona del grupo que consiste en fenilo y anillo heteroarilo monociclico de 5 o 6 miembros, en donde el fenilo y heteroarilo de 5 o 6 miembros estan opcionalmente sustituidos con uno o mas sustituyentes seleccionados del grupo que consiste en halogeno, alquilo C1-4, O (oxo), S (sulfinilo), alcoxi C1-4, entre otros. Las composiciones que comprenden estos compuestos y a metodos de tratamiento de enfermedades e infecciones bacterianas por Enterobacteriaceae. Los compuestos encuentran aplicacion en el tratamiento de infecciones y enfermedades provocadas por Enterobacteriaceae.
PE2022000118A 2017-11-03 2018-11-02 Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae" PE20221006A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1718285.8A GB201718285D0 (en) 2017-11-03 2017-11-03 Antibacterial Compounds
PCT/GB2018/053183 WO2019086890A1 (en) 2017-11-03 2018-11-02 Antibacterial compounds

Publications (1)

Publication Number Publication Date
PE20221006A1 true PE20221006A1 (es) 2022-06-15

Family

ID=60664899

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2020000454A PE20211390A1 (es) 2017-11-03 2018-11-02 Compuestos antibacterianos
PE2022000118A PE20221006A1 (es) 2017-11-03 2018-11-02 Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae"

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2020000454A PE20211390A1 (es) 2017-11-03 2018-11-02 Compuestos antibacterianos

Country Status (22)

Country Link
US (2) US11345694B2 (es)
EP (1) EP3704105B1 (es)
JP (2) JP7348897B2 (es)
KR (1) KR102470319B1 (es)
CN (1) CN111566099B (es)
AU (1) AU2018361828B2 (es)
BR (1) BR112020008531A2 (es)
CA (1) CA3081423A1 (es)
CL (2) CL2020001147A1 (es)
CO (1) CO2020005420A2 (es)
EA (1) EA202091118A1 (es)
GB (1) GB201718285D0 (es)
GE (1) GEP20237522B (es)
IL (1) IL274229B2 (es)
MA (1) MA50504A (es)
MX (2) MX2020004562A (es)
NZ (1) NZ764310A (es)
PE (2) PE20211390A1 (es)
SG (1) SG11202003717UA (es)
UA (1) UA128475C2 (es)
WO (1) WO2019086890A1 (es)
ZA (1) ZA202002093B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
AR114793A1 (es) 2018-04-18 2020-10-14 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN111635372B (zh) * 2020-06-28 2022-05-27 齐鲁工业大学 一种恶唑酮衍生物及其合成方法
KR20240004494A (ko) 2021-05-03 2024-01-11 디스쿠바 엘티디. 항균성 화합물
TW202340531A (zh) 2022-02-21 2023-10-16 日商三井化學股份有限公司 金屬構件、金屬樹脂接合體及金屬構件之製造方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA869348B (en) 1985-12-12 1987-10-28 Smithkline Beckman Corp Inhibition of the 5-lipoxygenase pathway
US4780470A (en) * 1986-08-19 1988-10-25 Smithkline Beckman Corporation Inhibition of interleukin-1 by monocytes and/or macrophages
JP2808460B2 (ja) * 1989-11-16 1998-10-08 大正製薬株式会社 イミダゾール誘導体
JPH09124640A (ja) 1995-08-25 1997-05-13 Nippon Soda Co Ltd ピリジルイミダゾール化合物、製法および農園芸用殺菌剤
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
AR029803A1 (es) * 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
AU2003249977A1 (en) 2002-07-05 2004-01-23 Axxima Pharmaceuticals Ag Imidazole compounds for the treatment of hepatitis c virus infections
JP2004196678A (ja) 2002-12-17 2004-07-15 Dainippon Pharmaceut Co Ltd ピラゾール系誘導体
DK1692113T3 (en) 2003-11-14 2018-01-08 Lorus Therapeutics Inc ARYLIMIDAZOLES AND USE THEREOF AS ANTICANCES
RU2367661C2 (ru) * 2004-03-05 2009-09-20 Тайсо Фармасьютикал Ко., Лтд. Производные тиазола
JP2007277230A (ja) * 2006-03-15 2007-10-25 Tanabe Seiyaku Co Ltd 医薬組成物
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
EP2513064B1 (en) 2009-12-17 2018-07-04 Katholieke Universiteit Leuven, K.U. Leuven R&D Compounds, compositions and methods for controlling biofilms
GB201016261D0 (en) 2010-09-28 2010-11-10 Univ Leuven Kath Compounds for controlling biofilms and process for their production
WO2012135016A2 (en) 2011-03-25 2012-10-04 North Carolina State University Inhibition of bacterial biofilms and microbial growth with imidazole derivatives
PL2731949T3 (pl) * 2011-07-13 2018-10-31 Tiumbio Co., Ltd. 2-pirydylo podstawione imidazole jako inhibitory alk5 i/lub alk4
US8840912B2 (en) 2012-01-09 2014-09-23 North Carolina State University Imidazole derivatives useful for controlling microbial growth
EP3142658B1 (en) * 2014-05-16 2020-01-15 Atriva Therapeutics GmbH Novel anti-infective strategy against influenza virus and s. aureus coinfections
PE20171789A1 (es) 2015-03-02 2017-12-28 Bristol Myers Squibb Co Inhibidores del factor beta de crecimiento de transformacion (tgf-beta)
US20180044316A1 (en) 2015-03-05 2018-02-15 University Of Notre Dame Du Lac Potentiators of beta-lactam antibiotics
EP3325473A4 (en) 2015-07-22 2019-06-26 The Royal Institution for the Advancement of Learning / McGill University Compounds and uses thereof in the treatment of cancer and other medical disorders
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds

Also Published As

Publication number Publication date
AU2018361828A1 (en) 2020-05-28
SG11202003717UA (en) 2020-05-28
IL274229B1 (en) 2023-01-01
CA3081423A1 (en) 2019-05-09
BR112020008531A2 (pt) 2020-10-20
JP2021501756A (ja) 2021-01-21
AU2018361828B2 (en) 2023-05-18
US20220372027A1 (en) 2022-11-24
MX2020004562A (es) 2020-08-13
EP3704105B1 (en) 2024-10-16
JP7348897B2 (ja) 2023-09-21
US20210163460A1 (en) 2021-06-03
NZ764310A (en) 2023-04-28
WO2019086890A1 (en) 2019-05-09
GB201718285D0 (en) 2017-12-20
CN111566099B (zh) 2023-06-02
IL274229A (en) 2020-06-30
ZA202002093B (en) 2023-11-29
CO2020005420A2 (es) 2020-07-31
CN111566099A (zh) 2020-08-21
EA202091118A1 (ru) 2020-08-06
US11345694B2 (en) 2022-05-31
CL2020001147A1 (es) 2020-08-14
JP2022025116A (ja) 2022-02-09
KR102470319B1 (ko) 2022-11-25
PE20211390A1 (es) 2021-07-27
MX2021010246A (es) 2021-09-21
GEP20237522B (en) 2023-08-10
MA50504A (fr) 2020-09-09
IL274229B2 (en) 2023-05-01
KR20200084875A (ko) 2020-07-13
CL2021002263A1 (es) 2022-04-01
UA128475C2 (uk) 2024-07-24
EP3704105A1 (en) 2020-09-09

Similar Documents

Publication Publication Date Title
PE20221006A1 (es) Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae"
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
AR116993A2 (es) Compuestos heterociclos bicíclicos y sus usos en terapia
CY1120834T1 (el) Δικυκλικες αζωτουχες ενωσεις ως αγωνιστες μουσκαρινικων υποδοχεων μ1
EA202091484A1 (ru) 4-азаиндольные соединения
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
EA202091483A1 (ru) Амидзамещенные индольные соединения, пригодные в качестве ингибиторов tlr
EA202091508A1 (ru) 6-азаиндольные соединения
CO2017004481A2 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
CL2018000292A1 (es) Compuestos farmacéuticos
EA202091480A1 (ru) Аминоиндольные соединения, пригодные в качестве ингибиторов tlr
ES2770058T3 (es) Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante
PE20170127A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
EA201500557A1 (ru) Антигельминтные соединения, композиции и способы их применения
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
PE20181074A1 (es) Compuestos heteroaromaticos como inhibidores de btk
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
PE20091005A1 (es) N-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров
CY1124795T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια και προφυλαξη λοιμωξεων χειρουργικης θεσης
PE20190968A1 (es) Compuestos de heterociclo tetraciclicos utiles como inhibidores de la integrasa del vih
ECSP088926A (es) Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina